| Irritable bowel syndrome with diarrhea
Viberzi vs Xifaxan
Side-by-side clinical, coverage, and cost comparison for irritable bowel syndrome with diarrhea.Deep comparison between: Viberzi vs Xifaxan with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXifaxan has a higher rate of injection site reactions vs Viberzi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xifaxan but not Viberzi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Viberzi
Xifaxan
At A Glance
Oral
Twice daily
Mixed opioid receptor agonist-antagonist
Oral
2-3 times daily
Rifamycin-class antibacterial
Indications
- Irritable bowel syndrome with diarrhea
- Traveler's diarrhea
- Hepatic Encephalopathy
- Irritable bowel syndrome with diarrhea
Dosing
Irritable bowel syndrome with diarrhea 100 mg orally twice daily with food; reduce to 75 mg twice daily in patients unable to tolerate 100 mg, receiving concomitant OATP1B1 inhibitors, with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment, or with moderate or severe renal impairment (eGFR <60 mL/min/1.73 m2) or ESRD not yet on dialysis.
Traveler's diarrhea 200 mg orally 3 times a day for 3 days.
Hepatic Encephalopathy 550 mg orally 2 times a day.
Irritable bowel syndrome with diarrhea 550 mg orally 3 times a day for 14 days; patients with recurrent symptoms may be retreated up to 2 times with the same regimen.
Contraindications
- Absence of a gallbladder (increased risk of pancreatitis and/or sphincter of Oddi spasm)
- Known or suspected biliary duct obstruction, or sphincter of Oddi disease or dysfunction
- Alcoholism, alcohol abuse or addiction, or consumption of more than 3 alcoholic beverages per day
- History of pancreatitis, or structural diseases of the pancreas including known or suspected pancreatic duct obstruction
- Known hypersensitivity reaction to eluxadoline or any excipient
- Severe hepatic impairment (Child-Pugh Class C)
- History of chronic or severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction
- Hypersensitivity to rifaximin, any rifamycin antimicrobial agents, or any components of XIFAXAN
Adverse Reactions
Most common (>2%) Constipation, nausea, abdominal pain, upper respiratory tract infection, vomiting, nasopharyngitis, abdominal distention, bronchitis, dizziness, flatulence, rash, increased ALT, fatigue, viral gastroenteritis
Serious Pancreatitis, sphincter of Oddi spasm
Postmarketing Anaphylaxis, angioedema, dyspnea, throat tightness, chest pain/tightness (hypersensitivity reactions)
Most common (>=5%) in hepatic encephalopathy Peripheral edema, nausea, dizziness, fatigue, ascites, muscle spasms, pruritus, abdominal pain, anemia, depression, nasopharyngitis, arthralgia, dyspnea, pyrexia, rash
Most common (>=2%) in travelers' diarrhea and IBS-D Headache, nausea, ALT increased
Postmarketing C. difficile-associated colitis, exfoliative dermatitis, angioneurotic edema, urticaria, flushing, pruritus, anaphylaxis, rhabdomyolysis, Stevens-Johnson syndrome, toxic epidermal necrolysis
Pharmacology
Eluxadoline is a mixed opioid receptor modulator that acts as a mu-opioid receptor agonist and kappa-opioid receptor agonist while simultaneously antagonizing the delta-opioid receptor, interacting locally with opioid receptors in the gut to reduce IBS-D symptoms.
Rifaximin is a rifamycin-class semi-synthetic antibacterial that inhibits bacterial DNA-dependent RNA polymerase by binding to its beta-subunit, blocking transcription and inhibiting bacterial protein synthesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Viberzi
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (6/12) · Qty limit (9/12)
Xifaxan
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (3/12) · Qty limit (9/12)
UnitedHealthcare
Viberzi
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (5/8)
Xifaxan
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (2/8) · Qty limit (6/8)
Humana
Viberzi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Xifaxan
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$30/fillfill
Viberzi Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableBausch Health Patient Assistance Program
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ViberziView full Viberzi profile
XifaxanView full Xifaxan profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.